Interference of bone marrow CD56(+) mesenchymal stromal cells in minimal residual disease investigation of neuroblastoma and other CD45(-)/CD56(+) pediatric malignancies using flow cytometry
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F19%3A10395191" target="_blank" >RIV/00064203:_____/19:10395191 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/19:10395191
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=F77S0Rn1y9" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=F77S0Rn1y9</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/pbc.27799" target="_blank" >10.1002/pbc.27799</a>
Alternative languages
Result language
angličtina
Original language name
Interference of bone marrow CD56(+) mesenchymal stromal cells in minimal residual disease investigation of neuroblastoma and other CD45(-)/CD56(+) pediatric malignancies using flow cytometry
Original language description
Background Bone marrow (BM) samples obtained from minimal residual disease (MRD)-negative children with B-cell acute lymphoblastic leukemia (B-ALL) were used in our laboratory as negative biological controls for the development of a neuroblastoma (NBL) flow-cytometric (FC) protocol. The accidental, but systematic, identification of rare cell populations (RCP) mimicking NBL cells (CD45(-)/CD56(+)) in these samples indicated the need for their thorough immunophenotypic identification, in order to elucidate their possible interference in NBL-MRD assessment. Procedure RCP observed in BM samples from 14 children recovering from BM aplasia due to intensive chemotherapy for B-ALL were investigated with the following markers: CD81, CD200, CD24, GD2, CD73, CD13, CD90, CD146, CD9, CD117, CD10, CD99, and NG2. BM samples from six newly diagnosed patients with NBL and an NBL cell line were simultaneously investigated as positive controls. Results The frequency of RCP in B-ALL BM samples was < 1/1 x 10(4) cells (bulky lysis), and their immunophenotypic profile was indicative of CD56(+) mesenchymal stromal cells (MSCs) (CD45(-), CD90(+), CD146(+), CD73(+)). Also, RCP expressed CD81 and CD200, simulating NBL cells. The most useful discriminative markers for CD56(+) MSCs were CD13 and CD73. An appropriate protocol consisting of two tubes with seven color combinations was further proposed: SYTO-16, GD2 (first tube) or CD73 (second tube)-PE, CD24-ECD, CD13-PC5.5, CD45-PC7, CD81-APC, and CD56-APC700. Conclusions RCP that were immunophenotypically similar to NBL were identified as CD56(+) MSCs. As these cells might pose an obstacle to accurate NBL disease assessment by FC, especially MRD, an enhanced NBL-FC protocol is proposed for prospective evaluation.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Pediatric Blood and Cancer
ISSN
1545-5009
e-ISSN
—
Volume of the periodical
66
Issue of the periodical within the volume
8
Country of publishing house
US - UNITED STATES
Number of pages
8
Pages from-to
e27799
UT code for WoS article
000472549200002
EID of the result in the Scopus database
2-s2.0-85065499634